A5004002355- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hemophilia Treatment and Research
- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Mast cells and histamine
- Vitamin K Research Studies
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Sinusitis and nasal conditions
- Cancer Immunotherapy and Biomarkers
- Chronic Myeloid Leukemia Treatments
- Contact Dermatitis and Allergies
- Intramuscular injections and effects
- Eosinophilic Esophagitis
- Nasal Surgery and Airway Studies
- Eosinophilic Disorders and Syndromes
- Asthma and respiratory diseases
- Blood Coagulation and Thrombosis Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Dye analysis and toxicity
- Beetle Biology and Toxicology Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Proteins in Food Systems
University of Colorado Colorado Springs
2012-2024
Charité - Universitätsmedizin Berlin
2024
Humboldt-Universität zu Berlin
2024
Semmelweis University
2024
Goethe University Frankfurt
2024
University Hospital Frankfurt
2024
La Jolla Alcohol Research
2023
Structural Analytics (United States)
2023
Allergy, Asthma and Clinical Research Center
2013
Tulane University
2004-2006
Current treatments for long-term prophylaxis in hereditary angioedema have limitations.To assess the efficacy of lanadelumab, a fully human monoclonal antibody that selectively inhibits active plasma kallikrein, preventing attacks.Phase 3, randomized, double-blind, parallel-group, placebo-controlled trial conducted at 41 sites Canada, Europe, Jordan, and United States. Patients were randomized between March 2016, September 9, 2016; last day follow-up was April 13, 2017. Randomization 2:1...
Approved on-demand treatments for hereditary angioedema attacks need to be administered parenterally, a route of administration that is associated with delays in treatment or withholding therapy.
Chronic rhinosinusitis is a common, high-morbidity chronic inflammatory disease, and patients often experience suboptimal outcomes with current medical treatment. The exhalation delivery system fluticasone (EDS-FLU) may improve care by increasing superior/posterior intranasal corticosteroid deposition.
Background & AimsWe evaluated treatment withdrawal, long-term outcomes, and safety of budesonide oral suspension (BOS) 2.0 mg twice daily in patients with eosinophilic esophagitis who completed a 12-week induction study.MethodsInduction full responders (≤6 eosinophils per high-power field [eos/hpf] ≥30% reduction the Dysphagia Symptom Questionnaire score) to BOS (ORBIT1/SHP621-301/NCT02605837) were randomized continue (BOS–BOS) or withdraw placebo (BOS–PBO) for 36 weeks...
Abstract Background Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency C1 inhibitor (C1‐ INH ‐ HAE ) by reducing the frequency attacks. Avoralstat is a small molecule kallikrein. This study ( OP uS‐2) evaluated efficacy and safety prophylactic avoralstat 300 or 500 mg compared placebo. Methods uS‐2 was Phase 3, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Subjects were...
Hereditary angioedema (HAE) is a rare genetic disorder characterized by painful, debilitating, and potentiallyfatal swelling attacks. Lanadelumab approved as long-term prophylaxis (LTP) in patients with HAE. However, realworld data on LTP use HAE are limited.
Abstract Background Human plasma‐derived nanofiltered C1 esterase inhibitor (C1 INH ‐nf) is used to treat acute angioedema attacks in patients with hereditary ( HAE ), but data regarding use children are sparse. Methods Patients 2 <12 years of age, body weight ≥10 kg, a diagnosis type I or II , were recruited for multicenter open‐label trial. into categories (10–25 >25 kg). Each category included dosing levels: ‐nf (500 units [U], 1000 U) and (1000 U, 1500 U), respectively....
Abstract Background Patients with hereditary angioedema C1 inhibitor deficiency or dysfunction have burdensome recurrent attacks. The safety, efficacy, and health‐related quality of life (HRQoL) outcomes (C1‐INH) prophylaxis (intravenously administered) in patients aged 6‐11 years were investigated. Methods Eligible enrolled a randomized, single‐blind, crossover, phase 3 trial. After 12‐week baseline observation period (BOP), received 500 1000 U C1‐INH, twice weekly, for 12 weeks before...
Hereditary angioedema (HAE), an inherited deficiency offunctional C1 esterase inhibitor (C1-INH), is characterized byrecurrent episodes of disabling and often painful swelling insubcutaneous and/or submucosal tissues.1HAE attacks aregenerally unpredictable, but triggers for attack can includehaving a dental or medical procedure (eg, surgery), other trauma,or stress. A preemptive management plan patients under-going these types situations may reduce the risk HAE at-tacks. Recommendations...
Hereditary angioedema (HAE) is a rare genetic condition characterized by painful and often debilitating swelling attacks. Little known about the differences in outcomes between patients with HAE types I or II (type I: caused C1 esterase inhibitor deficiency; type II: dysfunction), decreased dysfunctional (C1-INH), those normal C1-INH (nC1-INH-HAE).
Hereditary angioedema (HAE) is a complex disorder with wide array of treatment options. Shared decision-making (SDM) should be used to ensure that patients are choosing their best option. The goal was develop and psychometrically test brief instrument for assessing the patient's perspective SDM process during his or her clinical encounters an HAE specialist/allergist.
<b><i>Background:</i></b> Hereditary angioedema (HAE) is a rare genetic disease causing unpredictable and potentially life-threatening subcutaneous submucosal edematous attacks. Cinryze® (Shire ViroPharma Inc., Lexington, MA, USA), nanofiltered C1 inhibitor (C1-INH), approved in Europe for the treatment, preprocedure prevention, routine prophylaxis of HAE attacks, attacks USA. This phase 3 study assessed safety efficacy 2 C1-INH doses preventing children aged 6-11...
BackgroundBerotralstat is a first-line, once-daily oral plasma kallikrein inhibitor approved for prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years or older.ObjectiveThis analysis examined the safety and effectiveness long-term with berotralstat.MethodsAPeX-2 was phase 3, parallel-group, multicenter trial HAE caused by C1-inhibitor deficiency (NCT03485911). Part 1 randomized, double-blind, placebo-controlled evaluation 150 110 mg berotralstat over 24 weeks. In part 2,...
Summary Background There is concern that shrimp‐allergic individuals may react to glucosamine‐containing products as shrimp shells are a major source of glucosamine used for human consumption. Objective The purpose this study was determine whether can tolerate therapeutic doses glucosamine. Methods Subjects with history allergy were recruited and tested both reactivity via prick skin test shrimp‐specific IgE by an ImmunoCAP assay. Fifteen subjects positive tests class level two or greater...
Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of potentially life-threatening edema. The plasma kallikrein inhibitor ecallantide approved for treatment acute HAE attacks. This study evaluates the efficacy and safety multiple episodes in DX-88/19 (continuation) study. Patients received 30 mg subcutaneous attack symptoms, with no limit on number treated. Primary end point was change patient-reported mean symptom complex severity (MSCS) score at 4 hours....
BackgroundHereditary angioedema (HAE) with C1 inhibitor deficiency (C1-INH) is characterized by swelling of subcutaneous and/or submucosal tissues.ObjectiveTo evaluate efficacy/safety fixed-dose plasma-derived C1-INH (pdC1-INH) liquid for HAE attack prevention (NCT02584959).MethodsEligible patients were ≥12 years ≥2 monthly attacks prescreening or pre–long-term prophylaxis. In a partial crossover design, 80% randomized to placebo pdC1-INH 14 weeks and crossed over from active vice versa...
The 10th C1-inhibitor deficiency workshop will be held between 18 and 21 May 2017 in Budapest (2017.haenetworkshop.hu),among the picturesque surroundings of Margaret Island.As indicated by name this event, most interest focused on angioedema due to 1999, when it was first organized.The is unchanged, but range angioedemas has expanded since include all known varieties hereditary acquired with a bradykinin-mediated pathomechanism.Looking back agenda biennial conference, many questions remained...